'Disturbing' Disparity in Use of Key Breast Cancer Drug

'Disturbing' Disparity in Use of Key Breast Cancer Drug

The purpose of the study was to investigate the rates and patterns of receipt of trastuzumab in patients with early HER2-positive breast cancer (stages I-III) diagnosed in 2010 and 2011. Using the SEER-Medicare database, investigators examined a

(Visited 1 times, 1 visits today)
1
Like
Save

Comments

Write a comment

*